Kailera Therapeutics, Inc.(KLRA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KLRA Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Kailera Therapeutics, Inc. (KLRA), a Healthcare sector company. KLRA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of KLRA by reported 13-F value include BAIN CAPITAL INVESTORS, Bain Capital Life Sciences Investors, RTW INVESTMENTS, based on the most recent SEC filings. KLRA trades on the Nasdaq exchange and files with the SEC under CIK 2096997. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KLRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kailera Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-111.3M
ROIC
Q2 2026
-43.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProTotal Assets
| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Total Assets | $692.3M | — |
Get alerted when KLRA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kailera Therapeutics, Inc. including:
Top Institutional Holders of KLRA
BAIN CAPITAL INVESTORS LLC
$578.4M26,255,581 shBain Capital Life Sciences Investors, LLC
$497.5M22,583,268 shRTW INVESTMENTS, LP
$237.4M10,776,820 shCANADA PENSION PLAN INVESTMENT BOARD
$160.9M7,304,688 shAtlas Venture Life Science Advisors, LLC
$113.9M5,171,282 shFMR LLC
$87.5M3,970,865 shBlackRock, Inc.
$86.5M3,928,604 shPRICE T ROWE ASSOCIATES INC /MD/
$77.9M3,534,410 shCITADEL ADVISORS LLC
$71.4M3,240,787 shADAGE CAPITAL PARTNERS GP, L.L.C.
$70.7M3,208,286 sh
| Fund | Value | Shares |
|---|---|---|
| BAIN CAPITAL INVESTORS LLC | $578.4M | 26,255,581 |
| Bain Capital Life Sciences Investors, LLC | $497.5M | 22,583,268 |
| RTW INVESTMENTS, LP | $237.4M | 10,776,820 |
| CANADA PENSION PLAN INVESTMENT BOARD | $160.9M | 7,304,688 |
| Atlas Venture Life Science Advisors, LLC | $113.9M | 5,171,282 |
| FMR LLC | $87.5M | 3,970,865 |
| BlackRock, Inc. | $86.5M | 3,928,604 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $77.9M | 3,534,410 |
| CITADEL ADVISORS LLC | $71.4M | 3,240,787 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $70.7M | 3,208,286 |
More Healthcare Companies
View all Healthcare →Put KLRA on your watchlist
Track score changes the day Kailera Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KLRA a good stock to buy?
13F Pro's AI-powered analysis of Kailera Therapeutics, Inc. (KLRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KLRA are available on the KLRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KLRA is classified as a small company.
Which hedge funds own KLRA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KLRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kailera Therapeutics, Inc.'s investment landscape.